The Asia Pacific heparin market size is poised to grow substantially through 2026. The huge patient pool in highly populated countries like China and India is prone to various types of chronic illness, which will propel the market growth. For instance, the Asia Pacific Thrombosis Advisory Board’s research showed that venous thromboembolism (VTE) was one of the most common disorders in the Asian population in 2017, further elaborating that the VTE incidence rate was around 100 per 100,000 population per annum. The rising number of such chronic disorders will expand regional market growth.
Get sample copy of this research report @ https://www.decresearch.com/request-sample/detail/4837
The low molecular weight heparin market revenue was USD 3.6 billion in 2019 and the rising usage of the product in surgeries and the treatment of coagulation disorders will surge the industry demand. Moreover, researchers are creating synthetic heparin, finding it safer and cost-effective than the heparin derived from animals. For instance, researchers at the University of North Carolina (UNC) and the Rensselaer Polytechnic Institute created a safer and affordable synthetic form of low molecular weight heparin that can be reversed in activity using an antidote known as protamine
Online pharmacy in the global heparin market distribution channel landscape accounted for a 14.7% share in 2019. The benefits like substantial discounts, doorstep delivery, and availability of a broad range of products are expected to augment the segment demand. Also, the inclination of the young population and millennials towards online shopping in developing economies will fuel the segmental growth in the coming years.
Porcine, as a source segment, accounted for 98.8% of the global heparin market share in 2019. The use of porcine heparin to prevent blood clots during dialysis & blood transfusion; while collecting the blood samples and after surgery; is expected to surge the segment demand. Moreover, the increasing use of porcine heparin in patients suffering from atrial fibrillation will augment the segmental growth through 2026.
For instance, Amphastar Pharmaceuticals in 2018 launched a new drug application supplement for producing a semi-purified heparin at its subsidiary location. The product also received approval from the U.S. FDA in the same year. Sanofi, Laboratorios Farmaceuticos Rovi SA, Leo Pharma Hepalink group, and Pfizer are a few of the other firms in the sector.
Request for customization @ https://www.decresearch.com/roc/4837
Partial Chapter of the Table of Content
Chapter 4 Heparin Market, By Product
4.1 Key segment trends
4.2 Low molecular weight heparin
4.2.1 Market size, by region, 2015 - 2026 (USD Million)
4.3 Unfractionated heparin
4.3.1 Market size, by region, 2015 - 2026 (USD Million)
Chapter 5 Heparin Market, By Source
5.1 Key segment trends
5.2.1 Market size, by region, 2015 - 2026 (USD Million)
5.3.1 Market size, by region, 2015 - 2026 (USD Million)
Chapter 6 Heparin Market, By Application
6.1 Key segment trends
6.2 Venous thromboembolism
6.2.1 Market size, by region, 2015 - 2026 (USD Million)
6.3 Atrial fibrillation/flutter
6.3.1 Market size, by region, 2015 - 2026 (USD Million)
6.4 Coronary artery disease
6.4.1 Market size, by region, 2015 - 2026 (USD Million)
6.5.1 Market size, by region, 2015 - 2026 (USD Million)
Browse full table of contents (TOC) of this report @ https://www.decresearch.com/toc/detail/heparin-market
Browse Related Reports:
1. Left Atrial Appendage Closure Devices Market Regional Outlook, Application Potential, Covid-19 Impact Analysis, Competitive Market Share & Forecast, 2021 – 2027
2. Bariatric Surgery Devices Market Regional Outlook, Application Potential, Covid-19 Impact Analysis, Competitive Market Share & Forecast, 2021 – 2027